v3.26.1
Consolidated Condensed Balance Sheets - USD ($)
$ in Thousands
Jun. 27, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 29,457 $ 51,238
Accounts receivable, net 138,406 128,303
Inventory 79,807 82,236
Prepaid and other current assets 9,857 11,065
Total current assets 257,527 272,842
Property and equipment, net 20,527 21,899
Goodwill 7,462 7,462
Intangible assets, net 351,046 368,419
Operating lease assets 4,225 5,122
Deferred tax assets 29,052 5,522
Investment and other assets 3,507 2,293
Total assets 673,346 683,559
Current liabilities:    
Accounts payable 20,196 10,928
Accrued liabilities 109,361 130,242
Current portion of long-term debt 18,750 15,000
Other current liabilities 4,144 4,210
Total current liabilities 152,451 160,380
Long-term debt, less current portion 229,702 278,951
Deferred income tax liabilities 568 433
Other long-term liabilities 13,213 15,348
Total liabilities 395,934 455,112
Commitments and contingencies (Note 11)
Stockholders’ Equity    
Additional paid-in capital 527,925 520,851
Accumulated deficit (298,375) (334,929)
Accumulated other comprehensive loss (1,328) (1,900)
Total stockholders’ equity attributable to Bioventus Inc. 228,306 184,105
Noncontrolling interest 49,106 44,342
Total stockholders’ equity 277,412 228,447
Total liabilities and stockholders’ equity 673,346 683,559
Common Class A    
Stockholders’ Equity    
Common stock, value 68 67
Common Class B    
Stockholders’ Equity    
Common stock, value $ 16 $ 16